Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AIS Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

NCT01889238
View directory record Official record
Conditions
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
95
States / cities
Colorado Springs, Colorado • Lakewood, Colorado • Lone Tree, Colorado + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Terminated Phase 3 Interventional

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

NCT02438007
View directory record Official record
Conditions
Prostate Cancer
Interventions
Galeterone, Enzalutamide
Drug
Lead sponsor
LTN PHARMACEUTICALS, INC.
Industry
Eligibility
18 Years and older · Male only
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
51
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 24, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)

NCT04851873
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
OAV101
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting Not applicable Interventional

Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

NCT06052969
View directory record Official record
Conditions
Acute Ischemic Stroke AIS, Cerebral Arterial Disease
Interventions
Pulse NanoMED System
Device
Lead sponsor
Euphrates Vascular, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 24, 2026, 2:48 AM EDT
Completed No phase listed Observational

Lung Regeneration After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis

NCT03539770
View directory record Official record
Conditions
Scoliosis Idiopathic Adolescent
Interventions
Posterior spinal fusion
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Jul 24, 2026, 2:48 AM EDT
Completed Not applicable Interventional

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

NCT03990376
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Radioisotope I-131-labeled albumin
Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting Phase 1 Interventional

Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

NCT06705686
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
Interventions
(R)-9bMS
Drug
Lead sponsor
TechnoGenesys, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

NCT02689427
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03437941
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Exicorilant, Enzalutamide, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Active, not recruiting Phase 4 Interventional

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

NCT03016741
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions
GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

NCT02672475
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Galunisertib, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting Not applicable Interventional

Massage Therapy After Thoracic or Lumbar Surgery

NCT06424158
View directory record Official record
Conditions
Scoliosis; Adolescence, Adolescent Idiopathic Scoliosis, Thoracic Region, Adolescent Idiopathic Scoliosis, Lumbar Region
Interventions
Massage Therapy
Other
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
7 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jul 24, 2026, 2:48 AM EDT
Completed No phase listed Observational

Function and Scoliosis Surgery

NCT02237248
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 24, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional Results available

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

NCT03478904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide Liquid, Enzalutamide Capsule
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Jul 24, 2026, 2:48 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Self-Management Program for AIS D SCI

NCT05800717
View directory record Official record
Conditions
Psychological Well-Being, Spinal Cord Injuries
Interventions
SCI Self-Management for AIS D
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Completed Not applicable Interventional Results available

Use of Ultrasonic Bone Scalpel in Adolescent Idiopathic Scoliosis

NCT02781324
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis, Posterior Spinal Fusion
Interventions
Posterior Spinal Fusion, Ultrasonic Bone Scalpel
Procedure · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Jul 24, 2026, 2:48 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Incobotulinumtoxin A and Yoga-like Isometric Exercise in Adolescent Idiopathic Lumbar Scoliosis

NCT04922983
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis; Adolescence, Scoliosis; Lumbar Region
Interventions
Botulinum toxin type A, Isometric Yoga-like exercise, Placebo
Drug · Behavioral
Lead sponsor
Manhattan Physical Medicine and Rehabilitation, LLP
Other
Eligibility
14 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277
View directory record Official record
Conditions
Prostate Cancer
Interventions
AAA817, ARPI, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
25
States / cities
Palo Alto, California • Santa Barbara, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Advanced SPinal Innovations With Robotics and Enabling Technology Registry

NCT05071144
View directory record Official record
Conditions
Spine Deformity, Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis, Spondylolisthesis, Congenital Scoliosis, Neuromuscular Scoliosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 21 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

NCT02987829
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Interventions
TRC253
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 24, 2026, 2:48 AM EDT
Withdrawn No phase listed Observational

Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole

NCT01275651
View directory record Official record
Conditions
Prostate Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Jul 24, 2026, 2:48 AM EDT